These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 15059807)

  • 21. Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody.
    Lutgens E; Faber B; Schapira K; Evelo CT; van Haaften R; Heeneman S; Cleutjens KB; Bijnens AP; Beckers L; Porter JG; Mackay CR; Rennert P; Bailly V; Jarpe M; Dolinski B; Koteliansky V; de Fougerolles T; Daemen MJ
    Circulation; 2005 Jun; 111(25):3443-52. PubMed ID: 15967845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice.
    Erbel C; Chen L; Bea F; Wangler S; Celik S; Lasitschka F; Wang Y; Böckler D; Katus HA; Dengler TJ
    J Immunol; 2009 Dec; 183(12):8167-75. PubMed ID: 20007582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice.
    Atkinson RD; Coenen KR; Plummer MR; Gruen ML; Hasty AH
    Am J Physiol Endocrinol Metab; 2008 Feb; 294(2):E284-90. PubMed ID: 18029445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice.
    Yoshioka T; Okada T; Maeda Y; Ikeda U; Shimpo M; Nomoto T; Takeuchi K; Nonaka-Sarukawa M; Ito T; Takahashi M; Matsushita T; Mizukami H; Hanazono Y; Kume A; Ookawara S; Kawano M; Ishibashi S; Shimada K; Ozawa K
    Gene Ther; 2004 Dec; 11(24):1772-9. PubMed ID: 15496963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide.
    Recalde D; Ostos MA; Badell E; Garcia-Otin AL; Pidoux J; Castro G; Zakin MM; Scott-Algara D
    Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):756-61. PubMed ID: 14751811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD28-dependent differentiation into the effector/memory phenotype is essential for induction of arthritis in interleukin-1 receptor antagonist-deficient mice.
    Kotani M; Hirata K; Ogawa S; Habiro K; Ishida Y; Tanuma S; Horai R; Iwakura Y; Kishimoto H; Abe R
    Arthritis Rheum; 2006 Feb; 54(2):473-81. PubMed ID: 16453283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deficiency of inducible NO synthase reduces advanced but not early atherosclerosis in apolipoprotein E-deficient mice.
    Miyoshi T; Li Y; Shih DM; Wang X; Laubach VE; Matsumoto AH; Helm GA; Lusis AJ; Shi W
    Life Sci; 2006 Jul; 79(6):525-31. PubMed ID: 16516241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced atherosclerotic lesions in P2Y1/apolipoprotein E double-knockout mice: the contribution of non-hematopoietic-derived P2Y1 receptors.
    Hechler B; Freund M; Ravanat C; Magnenat S; Cazenave JP; Gachet C
    Circulation; 2008 Aug; 118(7):754-63. PubMed ID: 18663083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice.
    Danzaki K; Matsui Y; Ikesue M; Ohta D; Ito K; Kanayama M; Kurotaki D; Morimoto J; Iwakura Y; Yagita H; Tsutsui H; Uede T
    Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):273-80. PubMed ID: 22116098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice.
    George J; Afek A; Abashidze A; Shmilovich H; Deutsch V; Kopolovich J; Miller H; Keren G
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2636-41. PubMed ID: 16195475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of interleukin-15 in mouse and human atherosclerotic lesions.
    Wuttge DM; Eriksson P; Sirsjö A; Hansson GK; Stemme S
    Am J Pathol; 2001 Aug; 159(2):417-23. PubMed ID: 11485899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.
    Kitayama K; Nishizawa T; Abe K; Wakabayashi K; Oda T; Inaba T; Amemiya Y
    J Pharm Pharmacol; 2006 Dec; 58(12):1629-38. PubMed ID: 17331327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.
    Paul A; Ko KW; Li L; Yechoor V; McCrory MA; Szalai AJ; Chan L
    Circulation; 2004 Feb; 109(5):647-55. PubMed ID: 14744975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repopulation of apolipoprotein E knockout mice with CCR2-deficient bone marrow progenitor cells does not inhibit ongoing atherosclerotic lesion development.
    Guo J; de Waard V; Van Eck M; Hildebrand RB; van Wanrooij EJ; Kuiper J; Maeda N; Benson GM; Groot PH; Van Berkel TJ
    Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1014-9. PubMed ID: 15774908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo.
    Veillard NR; Steffens S; Pelli G; Lu B; Kwak BR; Gerard C; Charo IF; Mach F
    Circulation; 2005 Aug; 112(6):870-8. PubMed ID: 16061736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term administration of 3-deazaadenosine does not alter progression of advanced atherosclerotic lesions in apolipoprotein E-deficient mice.
    Preusch MR; Bea F; Yang SH; Kreuzer J; Isermann B; Pedal I; Rosenfeld ME; Katus HA; Blessing E
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):206-12. PubMed ID: 17703138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of endogenous IL-10 in LPS-induced STAT3 activation and IL-1 receptor antagonist gene expression.
    Carl VS; Gautam JK; Comeau LD; Smith MF
    J Leukoc Biol; 2004 Sep; 76(3):735-42. PubMed ID: 15218058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice.
    Huo Y; Zhao L; Hyman MC; Shashkin P; Harry BL; Burcin T; Forlow SB; Stark MA; Smith DF; Clarke S; Srinivasan S; Hedrick CC; Praticò D; Witztum JL; Nadler JL; Funk CD; Ley K
    Circulation; 2004 Oct; 110(14):2024-31. PubMed ID: 15451785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice.
    Bengtsson E; To F; Håkansson K; Grubb A; Brånén L; Nilsson J; Jovinge S
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2151-6. PubMed ID: 16051881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenoviral delivery of IL-1 receptor antagonist abrogates disease activity during the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice.
    Hur W; Cho ML; Yoon SK; Kim SY; Ju JH; Jhun JY; Heo SB; Moon YM; Min SY; Park SH; Kim HY
    Immunol Lett; 2006 Aug; 106(2):154-62. PubMed ID: 16793145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.